Relay Therapeutics, Inc.
RLAY
주식 순위
#4012
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
주가
$18.65
마지막 동기화: 2026-10-20
시가총액
$4.09B
변동 (1일)
9.15%
변동 (1년)
164.96%
국가
US
거래 Relay Therapeutics, Inc. (RLAY)
카테고리
Healthcare
Relay Therapeutics, Inc. (RLAY)의 매출
Jun 2026 기준 매출 TTM: $10.35M
Relay Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $10.35M입니다. 2023년에 회사는 $25.55M의 수익을 올렸으며 이는 2022년의 $1.38M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Relay Therapeutics, Inc.의 수익 기록 (2018 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $10.35M | 3.43% |
| 2024 | $10.01M | -60.83% |
| 2023 | $25.55M | 1,749.82% |
| 2022 | $1.38M | -54.41% |
| 2021 | $3.03M | -96.34% |
| 2020 | $82.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 121,873.91% |
US
|
|
| $2.23B | 21,426.57% |
US
|
|
| $15.74B | 152,019.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 58,076.69% |
NL
|
